{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:20:31Z","timestamp":1785903631833,"version":"3.56.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Heyde syndrome, the co-occurrence of aortic stenosis and bleeding gastrointestinal (GI) angiodysplasia, is managed with aortic valve replacement. However, severe bleeding and anemia can preclude safe use of the antiplatelet or anticoagulant therapy required for this intervention. We present a case of the novel and successful treatment of severe, refractory bleeding and transfusion dependence with antiangiogenic therapy in a patient with Heyde syndrome. After systemic bevacizumab was initiated, the patient achieved durable hemostasis with normalization of hemoglobin and liberation from red cell transfusion and dependence on iron infusion; aspirin therapy was successfully initiated where it had previously failed. This durable hemostasis facilitated her subsequent successful transcatheter aortic valve replacement. Plasma vascular endothelial growth factor levels, which were monitored during therapy, paradoxically rose after bevacizumab was initiated but normalized after it was discontinued. Given the angiogenic dysregulation of Heyde syndrome, systemic bevacizumab may be an effective and safe targeted therapy for managing refractory GI bleeding, which thereby facilitates antiplatelet therapy and aortic valve replacement in these challenging cases. Additional investigation into the therapeutic role of inhibiting angiogenesis as a hemostatic modality in Heyde syndrome is warranted.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004810","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T21:46:16Z","timestamp":1631223976000},"page":"3850-3854","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Systemic bevacizumab for refractory bleeding and transfusion-dependent anemia in Heyde syndrome"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6915-8733","authenticated-orcid":false,"given":"Andrew B.","family":"Song","sequence":"first","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA;"},{"name":"Harvard Medical School, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Sakhuja","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Cardiovascular Medicine, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Gracin","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Cardiovascular Medicine, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Weinger","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Massachusetts General\/North Shore Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj S.","family":"Kasthuri","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of North Carolina-Chapel Hill, Chapel Hill, NC; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA;"},{"name":"Division of Hematology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"issue":"12","key":"2021100715240005600_B1","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2011-02-306597","article-title":"Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor","volume":"118","author":"Crawley","year":"2011","journal-title":"Blood."},{"issue":"1","key":"2021100715240005600_B2","doi-asserted-by":"crossref","first-page":"e2013060","DOI":"10.4084\/mjhid.2013.060","article-title":"Von Willebrand factor, angiodysplasia and angiogenesis","volume":"5","author":"Randi","year":"2013","journal-title":"Mediterr J Hematol Infect Dis."},{"issue":"20","key":"2021100715240005600_B3","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMcibr1205363","article-title":"From clinical observation to mechanism--Heyde\u2019s syndrome","volume":"367","author":"Loscalzo","year":"2012","journal-title":"N Engl J Med."},{"issue":"3","key":"2021100715240005600_B4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5551\/jat.49239","article-title":"Disappearance of angiodysplasia following transcatheter aortic valve implantation in a patient with Heyde\u2019s syndrome: A case report and review of the literature","volume":"27","author":"Tsuchiya","year":"2020","journal-title":"J Atheroscler Thromb."},{"issue":"1","key":"2021100715240005600_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2018.09.041","article-title":"Blood disorders in patients undergoing transcatheter aortic valve replacement: A review","volume":"12","author":"De Larochelli\u00e8re","year":"2019","journal-title":"JACC Cardiovasc Interv."},{"issue":"5","key":"2021100715240005600_B6","first-page":"e72","article-title":"2020 ACC\/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation."},{"issue":"8","key":"2021100715240005600_B7","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica."},{"issue":"1","key":"2021100715240005600_B8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","article-title":"Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers","volume":"14","author":"Al-Samkari","year":"2019","journal-title":"Orphanet J Rare Dis."},{"issue":"6","key":"2021100715240005600_B9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/hae.14034","article-title":"An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"26","author":"Al-Samkari","year":"2020","journal-title":"Haemophilia."},{"issue":"6","key":"2021100715240005600_B10","doi-asserted-by":"crossref","first-page":"E313","DOI":"10.1002\/ajh.24367","article-title":"Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding","volume":"91","author":"Epperla","year":"2016","journal-title":"Am J Hematol."},{"issue":"2","key":"2021100715240005600_B11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ajg.2014.391","article-title":"Long-term therapy with bevacizumab in a patient with Glanzmann\u2019s thrombasthenia and recurrent digestive bleeding due to gastrointestinal angiodysplastic lesions","volume":"110","author":"Marlu","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"2021100715240005600_B12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al-Samkari","year":"2019","journal-title":"J Intern Med."},{"issue":"2","key":"2021100715240005600_B13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc."},{"issue":"35","key":"2021100715240005600_B14","doi-asserted-by":"crossref","first-page":"57197","DOI":"10.18632\/oncotarget.11084","article-title":"The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance","volume":"7","author":"Alidzanovic","year":"2016","journal-title":"Oncotarget."},{"issue":"5","key":"2021100715240005600_B15","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1203\/01.pdr.0000242494.94000.52","article-title":"The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts","volume":"60","author":"Segerstr\u00f6m","year":"2006","journal-title":"Pediatr Res."},{"issue":"31","key":"2021100715240005600_B16","doi-asserted-by":"crossref","first-page":"8136","DOI":"10.1200\/JCO.2005.02.5635","article-title":"Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients","volume":"23","author":"Willett","year":"2005","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021100715240005600_B17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/19\/3850\/1825915\/advancesadv2021004810.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/19\/3850\/1825915\/advancesadv2021004810.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T22:50:25Z","timestamp":1673218225000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/19\/3850\/476848\/Systemic-bevacizumab-for-refractory-bleeding-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":17,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2021,10,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004810","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]}}}